BioSpace News Archive

MiNK Therapeutics, today announced acceptance of three abstracts for presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held between November 10-14, 2021.

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, will present an oral presentation at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress being held in a virtual format from October 19-22, 2021, and two posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting,

Bolt Biotherapeutics, Inc. announced that it will be presenting three abstracts at the 2021 Society for Immunotherapy of Cancer’s 36th Annual Meeting, which is being held from Nov. 10-14, both virtually and in person in Washington, D.C.

Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced that it has closed its business combination with Montes Archimedes Acquisition Corp., a special purpose acquisition company, as well as a concurrent PIPE financing.

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced three upcoming poster presentations at the 36th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting, to be held in Washington, D.C., as well as virtually November 10-14, 2021.

Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced it will present initial data from its ongoing Phase 1 clinical trial of ONCR-177 at the upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place November 12–14, 2021 in Washington, D.C. and virtually.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, successfully hosted the fourth webinar in its virtual investor mini-series.

Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24).

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing translational data obtained in the DeCidE clinical study in patients with advanced, recurrent ovarian cancer will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 10-14, 2021 in Washington, DC.